An Experimental Treatment Using Modified Immune Cells to Treat Lupus (LMY-920)
Phase: Recruiting
Condition(s): Systemic lupus erythematosus (SLE)
NCT Number: NCT06340750
What Is the Purpose of This Study?
The purpose of this study is to find out if it is safe to give a type of cellular therapy called BAFF ligand CAR-T cells (LMY-920) manufactured by Luminary Therapeutics and to determine the recommended dose of CAR-T cells. We also hope to study how well the CAR-T cells work by evaluating how many patients’ lupus responds to the treatment.
Who Can Take Part in This Study?
People who may be eligible for this study:
- Are 18–69 years old.
- Have a confirmed diagnosis of systemic lupus erythematosus (SLE).
Have active lupus that meets the study’s requirements, based on symptoms, organ involvement, or certain types of lupus-related kidney inflammation confirmed by a recent kidney biopsy.
For a full list of eligibility requirements, visit https://clinicaltrials.gov/study/NCT06340750
What Will Happen During This Study?
- This early-stage study will evaluate the safety of LMY-920, an investigational CAR-T cell treatment, in adults whose lupus has not responded to treatment.
- Researchers will identify a dose for future studies and explore whether the treatment may reduce lupus activity.
- Participation includes screening and collection of your immune cells, followed by chemotherapy to prepare your body for the CAR-T cell infusion.
- After the infusion, follow-up visits will monitor your health, side effects, and lupus activity.